Standard BioTools Completes Asset Acquisition
Ticker: LAB · Form: 8-K · Filed: May 8, 2024 · CIK: 1162194
| Field | Detail |
|---|---|
| Company | Standard Biotools Inc. (LAB) |
| Form Type | 8-K |
| Filed Date | May 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, assets
TL;DR
Standard BioTools just bought some assets, filing shows.
AI Summary
Standard BioTools Inc. announced on May 8, 2024, the completion of its acquisition of assets from a third party. The company, formerly known as Fluidigm Corp, is headquartered in South San Francisco, California. This filing is a current report under the Securities Exchange Act of 1934.
Why It Matters
This filing indicates a strategic move by Standard BioTools to expand its asset base, which could impact its market position and future growth prospects.
Risk Assessment
Risk Level: low — The filing is a standard disclosure of an asset acquisition and does not contain information suggesting immediate or significant risk.
Key Players & Entities
- Standard BioTools Inc. (company) — Registrant
- Fluidigm Corp (company) — Former company name
- May 8, 2024 (date) — Date of report
- South San Francisco, California (location) — Principal executive offices
FAQ
What specific assets were acquired by Standard BioTools Inc.?
The filing does not specify the exact nature or details of the assets acquired, only that an acquisition of assets was completed.
What was the financial impact of this asset acquisition?
The filing does not disclose any specific dollar amounts or financial terms related to the asset acquisition.
When did the acquisition of assets officially close?
The acquisition of assets was completed on May 8, 2024, as reported in the filing.
Does this filing indicate any changes to Standard BioTools Inc.'s business operations?
While the acquisition of assets suggests a strategic expansion, the filing itself does not detail specific changes to ongoing business operations.
Is there any information about the third party from whom the assets were acquired?
No, the filing does not identify the third party involved in the asset acquisition.
Filing Stats: 591 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-05-08 16:31:44
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 par value per share LAB Nasdaq Glob
Filing Documents
- lab-20240508.htm (8-K) — 47KB
- lab-ex99_1.htm (EX-99.1) — 633KB
- 0000950170-24-055791.txt ( ) — 857KB
- lab-20240508.xsd (EX-101.SCH) — 51KB
- lab-20240508_htm.xml (XML) — 5KB
02 - Results of Operations and Financial Condition
Item 2.02 - Results of Operations and Financial Condition On May 8, 2024, Standard BioTools Inc. issued a press release which included information with respect to certain financial results for the three months ended March 31, 2024. The press release is attached hereto as Exhibit 99.1. The information set forth in the press release, except for the information set forth under the heading "Outlook for 2024" and under the heading "About Standard BioTools Inc.," together with the forward-looking statement disclaimer, is incorporated by reference into this Item 2.02 of this Current Report on Form 8-K.
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. The information set forth under the heading "Outlook for 2024" and under the heading "About Standard BioTools Inc.," together with the forward-looking statement disclaimer, is incorporated by reference into this Item 7.01 of this Current Report on Form 8-K.
01 - Financial Statements and Exhibits
Item 9.01 - Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press release issued by Standard BioTools Inc., dated May 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) The information in Item 2.02 and Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), or otherwise subject to the liabilities of that Section and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 8, 2024 STANDARD BIOTOOLS INC. By: /s/ Jeffrey Black Name: Jeffrey Black Title: Chief Financial Officer